Creyon Bio Appoints Serge Messerlian as CEO
Serge Messerlian, CEO and Chairman, Creyon Bio • Creyon Bio
SAN DIEGO, April 23, 2025 (BUSINESS WATCH GLOBAL) — Biotechnology company Creyon Bio has announced the appointment of Serge Messerlian as Chief Executive Officer. Messerlian, who previously served as Executive Chairman and Acting CEO, now assumes full leadership responsibilities effective immediately.
Corporate Business News Sponsored by VS News Network
Messerlian brings prior leadership experience in multinational pharmaceutical and biotechnology companies, having held executive roles at Teon Therapeutics, Janssen Oncology, Actelion, Baxalta, and Baxter International. At Janssen Oncology, a Johnson & Johnson company, he led the development and commercialization of cancer therapies. His background includes involvement in mergers and acquisitions, business development, and product oversight across therapeutic areas including oncology, immunology, and rare diseases.
According to the company, Messerlian will oversee advancement of the company’s dual strategy: developing a proprietary therapeutic pipeline while also pursuing external collaborations. Creyon’s platform centers on what it describes as the first AI-powered oligonucleotide engineering engine for designing tissue-specific, RNA-targeted oligonucleotide therapies.
“With the FDA’s recent commitment to phasing out traditional animal testing in favor of new approach methodologies, Creyon’s platform is uniquely positioned to lead this next chapter in drug development. Having collaborated closely with Creyon as an investor and board member, it’s an honor to step into the role of CEO as we prepare to enter clinical development in 2026 for our lead neuromuscular disease candidate which we plan to announce later this year. Creyon is committed to advancing our dual strategy of building our wholly owned therapeutic pipeline, while seeking collaboration opportunities to apply our technology across additional disease areas,” said Serge Messerlian, CEO, Creyon Bio.
Additionally, Kiersten Stead, Ph.D., Co-Founder and Managing Partner at DCVC Bio, has joined the company’s Board of Directors. DCVC Bio has been an investor in Creyon since 2020. Dr. Stead has prior experience in platform development, early-stage company formation, and investment in therapeutic technology companies.
“Serge brings the perfect blend of therapeutic development expertise and strategic, operational leadership that Creyon Bio needs as we advance our pipeline and our partnership opportunities. His proven track record in both rare and prevalent diseases, combined with our technology platforms, strengthens our ability to forge strategic alliances and deliver impactful oligo therapies within timelines that were previously unimaginable. We are also excited to welcome Dr. Stead, whose extensive experience in investing and contributing to company development and growth will be invaluable as we pivot into important neuromuscular, CNS, and immunologic diseases where we can have a significant impact,” said Shaq Vayda, Board Member and Principal, Lux Capital.
For more information, visit www.creyonbio.com.
Source: Creyon Bio
